Prostate Cancer: Related News

On Our Blog

Peter Scardino, Chair of MSK’s Department of Surgery and a specialist in the treatment of prostate cancers.
Predicting the Future of Cancer Surgery

Peter Scardino, Chair of MSK’s Department of Surgery, gives his views on what lies ahead for the surgical treatment of cancer.

February 24, 2015
Pictured: Michael Zelefsky
Smoking May Interfere with Radiation Treatment for Prostate Cancer

Researchers call for intensified efforts to help men with prostate cancer quit smoking after a recent MSK study revealed that patients who smoke during radiation therapy face a higher risk of both having the disease return and dying from it.

February 2, 2015
Pictured: Jaspreet Sandhu and Laura Leddy
For Urination Problems after Cancer Treatment, MSK Surgeons Can Help

Urinary problems like incontinence and overactive bladder can be an issue for cancer survivors. At MSK, our surgeons can offer a range of solutions.

January 26, 2015
Stained pathology slides of a patient’s tumor (right) and of an organoid made from that tumor (left).
Five Fascinating Approaches to Cancer Science

From tropical plants and 3-D snapshots of worms to tiny particles that light up tumors, here’s a glimpse at some of the fascinating work MSK researchers pursued in 2014 as part of our quest to advance cancer science.

December 30, 2014
Solutions for Chemotherapy-Related Nausea and Vomiting

With quick action and the help of the right medicine at the right time, chemotherapy-induced nausea and vomiting can often be prevented, says MSK Nurse Leader Corey Russell.

September 29, 2014
Prostate Cancer Organoids Provide New Tool for Evaluating Therapies

Researchers have created tiny structures called organoids from patients’ prostate tumors. These organoids will allow the study of tumors in greater detail and enable correlation of genetic mutations with drug response.

September 4, 2014
Memorial Sloan Kettering Transforms Cancer Research and Care Delivery

Memorial Sloan Kettering’s vision is nothing less than to revolutionize the treatment of cancer. Learn about some of the ways we’re doing it.

July 11, 2014
Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
New Biotech Startup Will Pit the Immune System Against Cancer

Memorial Sloan Kettering’s partnership in a pioneering effort to speed the development of cancer immunotherapies drew national headlines.

December 6, 2013
Pictured: Michael Zelefsky
Treating Prostate Cancer with a Missile-Like Delivery of High-Dose Radiation

Memorial Sloan Kettering offers patients with prostate cancer a comprehensive package of the most advanced radiation therapy approaches that enable more-personalized and effective care.

October 23, 2013
Pictured: Vincent Laudone and James Eastham
When "Do No Harm" Means "Do Nothing": Managing Risks

An earlier post about active surveillance as a management strategy for prostate cancer generated an engaged and meaningful discussion on this blog, especially about the risks of “doing nothing.” Here we take a closer look at the concept of risk.

September 20, 2013
Pictured: Vincent Laudone  & James Eastham
When “Do No Harm” Means “Do Nothing”

Active surveillance is the most appropriate management strategy for many men with prostate cancer, but often this option is never mentioned.

August 14, 2013
Pictured: Pramod Sogani
Pramod Sogani Inaugurated As President of the American Urological Association

Memorial Sloan Kettering urologic surgeon Pramod Sogani has been inaugurated as President of the American Urological Association. In this Q&A he discusses his goals and his new role.

July 1, 2013
Charles Sawyers, Kenneth Offit, and Larry Norton
Three Memorial-Sloan Kettering Researchers Receive Special Awards by the American Society of Clinical Oncology

Charles Sawyers, Larry Norton, and Kenneth Offit are being honored with special awards at the annual meeting of the world’s leading professional organization for cancer physicians and researchers.

May 22, 2013
Pictured: Charles Sawyers
Research Suggests a New Approach for Overcoming Resistance to a Targeted Therapy for Prostate Cancer

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

April 30, 2013
Pictured: Andrew Vickers
A Single Early PSA Test Found to Predict Long-Term Risk of Aggressive Prostate Cancer

A study led by Memorial Sloan Kettering investigators indicates nearly half of all prostate cancer deaths by age 75 occur in a small group of men with high PSA levels at age 45.

April 17, 2013
Pictured: Peter Scardino
Department of Surgery Chair Peter Scardino on Smarter Screening for Prostate Cancer

Dr. Scardino discusses strategies for how physicians and patients can make the best use of PSA testing and prostate cancer treatment.

March 14, 2013
Pictured: John Mulhall
Urologist John Mulhall Explains Strategies for Addressing Sexual Health Concerns for Men with Cancer

Dr. Mulhall, director of Memorial Sloan Kettering’s Male Sexual and Reproductive Medicine Program, explains common concerns about male sexual health and offers advice for men and their partners.

March 8, 2013
Pictured: Raul Parra
Meet Urologic Cancer Surgeon Raul Parra

Dr. Parra, who practices at Memorial Sloan Kettering Basking Ridge, treats prostate, kidney, and bladder cancers with the goal of extending the lives of patients, and giving them the best possible quality of life.

March 6, 2013
Pictured: David Finley & Maria Teresa Ruiz Tsukazan
Robot-Assisted Surgery at Memorial Sloan Kettering

Our doctors introduce and apply advanced technologies in minimal-access surgery to benefit patients.

February 25, 2013
Pictured: Bernard Bochner
Meet Urologic Surgeon Bernard Bochner

Dr. Bochner – who specializes in treating people with prostate, bladder, and kidney cancers – discusses the importance of a multidisciplinary team approach to delivering high-quality care.

January 11, 2013
Pictured: Michael Zelefsky
Medication Used Before, During, and After Radiation Treatment Helps Men with Prostate Cancer Maintain Overall Sexual Function

Study signals hope for maintaining sexual function in men undergoing radiation treatment for prostate cancer.

November 30, 2012
Pictured: PET Scan
New Imaging Agent Could Improve Prostate Cancer Diagnosis and Treatment

Researchers at Memorial Sloan Kettering are developing a new strategy for PET imaging of tumors that could result in new tools to detect and monitor prostate cancer.

November 15, 2012
Pictured: Charles Sawyers & Howard Scher
Targeted Therapy for Advanced Prostate Cancer Receives FDA Approval

Enzalutamide, a targeted therapy co-invented by a Memorial Sloan Kettering investigator, has received FDA approval for the treatment of men with metastatic prostate cancer.

August 31, 2012
Pictured: Karim Touijer
Meet Urologic Surgeon Karim Touijer

Watch urologic surgeon Karim Touijer discuss our comprehensive approach to cancer care and recent advances in minimally invasive surgery.

July 31, 2012
Pictured: Howard Scher
Memorial Sloan Kettering Experts Maintain That PSA Screening for Prostate Cancer Saves Lives

Memorial Sloan Kettering’s prostate cancer team — including Howard I. Scher, Chief of the Genitourinary Oncology Service — disagrees with new PSA screening recommendations released by government task force.

June 1, 2012
Pictured: American Association of Cancer Research Annual Meeting 2012
Memorial Sloan Kettering Discoveries in Personalized Medicine Highlighted at Major Cancer Research Meeting; Investigators Honored

The American Association for Cancer Research (AACR), the world’s oldest and largest professional organization dedicated to advancing cancer research, held its 2012 annual meeting in Chicago.

April 3, 2012
Pictured: Peter Scardino
Surgery’s Vital Role in Treating Cancer

Department of Surgery Chair Peter T. Scardino reflects on the expanding role of surgery at an institution devoted to caring for people with cancer.

March 12, 2012
Pictured: Memorial Sloan Kettering logo
Memorial Sloan Kettering Made Major Contributions to Cancer Advances in 2011

Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators.

February 6, 2012
Pictured: Charles Sawyers & Howard Scher
New Medical Strides against Prostate Cancer

The success of an experimental prostate cancer treatment is an example of how academic research centers are playing a larger role in drug development, the Wall Street Journal reports.

February 3, 2012
Pictured: Michael Morris
Bone Scan Index May Help Determine Response to Prostate Cancer Treatment

Researchers at Memorial Sloan Kettering have shown the usefulness of a scale called the Bone Scan Index (BSI) for determining whether some prostate cancer patients are responding to therapy.

January 13, 2012
Pictured: Charles Sawyers & Howard Scher
Positive Results in Clinical Trial for Advanced Prostate Cancer Drug

A late-stage clinical trial of a drug for advanced prostate cancer was stopped this week after it was found to extend survival by nearly five months.

November 4, 2011
Brett Carver
Memorial Sloan Kettering Researchers Discover How Prostate Cancer Disease Pathways Regulate Each Other

Memorial Sloan Kettering researchers have discovered that the AR and PI3K disease pathways regulate each other through reciprocal negative feedback.

July 1, 2011
Pictured: Jedd Wolchok & Paul Chapman
Memorial Sloan Kettering Physician-Scientists Present Significant Clinical Cancer Research Advances at ASCO Annual Meeting

In an extraordinary demonstration of excellence, five Memorial Sloan Kettering physician-scientists were selected to participate in the press program at the 2011 American Society of Clinical Oncology annual meeting, held June 3-7 in Chicago.

July 1, 2011

Related Media Coverage

Prostate Cancer Surgery May Impair Sex for Both Partners

Urologic surgeon Vincent Laudone explains how both members of a couple can experience diminished sexual function after a man has prostate cancer surgery.

February 14, 2015
Prostate Cancer Patients Who Smoke Fare Worse, Study Finds

Radiation oncologist Michael Zelefsky discusses his recent study published in the journal BMJ.

January 27, 2015
Questions Remain Over Role of PCA3 Assay in Prostate Cancer

Methodologist Andrew Vickers discusses the role of the prostate cancer antigen 3 (PCA3) in ruling out prostate cancer.

January 12, 2015
SU2C Dream Team: Revolutionary Treatment For Prostate Cancer

Physician-scientist Yu Chen is part of a Stand Up To Cancer “Dream Team” that is focused on prostate cancer research.

September 5, 2014
Custom-Fit Treatments for Prostate Cancer

Research led by radiation oncologist William Polkinghorn and physician-scientist Charles Sawyers suggests that analyzing a tumor’s DNA may identify prostate cancer patients who would benefit from radiation alone or in combination with other treatments.

January 14, 2014
New Debate on Prostate Cancer Drug

Prostate cancer surgeon Peter Scardino weighed in on a new study that has reignited a debate about whether men should use a baldness drug to prevent prostate cancer.

August 15, 2013
Urology Group Stops Recommending Routine PSA Test

Prostate cancer surgeon Peter Scardino commented on new PSA screening guidelines released by the American Urological Association.

May 3, 2013
Obesity Increases Men's Risk of Dying from Prostate Cancer

Epidemiologist Helena Furberg commented on a study that found that men who are overweight are more likely to have precancerous lesions detected in a benign prostate biopsy and are at a greater risk for subsequently developing prostate cancer.

April 23, 2013
Pared Back Prostate Cancer Screening May Save Lives

A study led by epidemiologist Andrew Vickers found that certain men may need only three PSA tests in their lifetime.

April 17, 2013
Cancer Diagnosis: Less Can Be More

Prostate cancer surgeon Peter Scardino was interviewed about prostate cancer screening tests.

March 26, 2013
Surgery Restoring Penis after Prostate Cancer Increasing

Director of Memorial Sloan Kettering’s Male Sexual and Reproductive Medicine Program John Mulhall discussed ways to improve sexual function after prostate cancer surgery.

March 25, 2013
Men Have More Options in Prostate Cancer Treatments

Medical oncologist Howard Scher commented on the growing arsenal of prostate cancer treatments.

October 1, 2012
Targeted Therapy Improves Overall Survival in Men with Late-Stage Prostate Cancer

The investigational oral drug MDV3100 significantly improved overall survival in patients with advanced prostate cancer, results of a large, phase III study show.

January 31, 2012
Drug Shown To Significantly Improve Survival In Men With Metastatic Prostate Cancer While Exploring A Potential Biomarker To Measure Treatment Response

The final survival analysis of an international study of a new drug for prostate cancer has found an even greater median survival benefit than previously reported, and has established a new class of treatment for men with metastatic prostate cancer. In addition, researchers are exploring a potential biomarker of response to treatment in general.

June 4, 2011
Drug Shown to Improve Overall Survival in Patients with Metastatic Prostate Cancer

An international, multi-center study has found that a recently FDA-approved drug called abiraterone acetate significantly improves overall survival in men with metastatic prostate cancer by more than 34 percent. Researchers at Memorial Sloan Kettering Cancer Center, the Institute of Cancer Research and the Royal Marsden Hospital in the UK as well as other cancer centers around the world published the findings in the May 26, 2011, issue of The New England Journal of Medicine.

May 25, 2011
Blood Test Given Earlier Than Recommended Predicts Long-Term Risk of Death from Prostate Cancer and Suggests Annual PSA Testing for Most Men is Unnecessary

A prostate-specific antigen (PSA) test taken for the first time between the ages of 44 and 50 can predict the likelihood that a man will die from prostate cancer over the next 25 to 30 years, according to researchers at Memorial Sloan Kettering Cancer Center.

May 19, 2011
Change in PSA Level Does Not Predict Prostate Cancer

Researchers at Memorial Sloan Kettering Cancer Center have found that change in PSA levels over time - known as PSA velocity - is a poor predictor of prostate cancer and may lead to many unnecessary biopsies.

February 24, 2011